Skip to main content

Posters

March 02, 2019
Background: Narcolepsy diagnosis can be challenging. Presence of comorbidities and overlapping symptoms between narcolepsy and other conditions may contribute to diagnostic delay and misdiagnosis. Objective: To describe the frequency of misdiagnoses and comorbidities in participants diagnosed with…
March 02, 2019
Background: Sleep problems are common in adults with attention-deficit/hyperactivity disorder (ADHD). This study examined the effect of baseline sleep quality on response to treatment with SHP465 mixed amphetamine salts (MAS) extended-release.
March 02, 2019
INTRODUCTION: Solriamfetol, a selective dopamine/norepinephrine reuptake inhibitor, significantly decreased excessive sleepiness in a randomized, double-blind, placebo-controlled study of adults with narcolepsy. Health-related quality of life (HRQoL) results (secondary endpoints) are reported here.
March 02, 2019
INTRODUCTION: Excessive sleepiness (ES) is a prominent symptom of narcolepsy and obstructive sleep apnea (OSA). Solriamfetol, a selective dopamine/norepinephrine reuptake inhibitor, was effective in treating ES in narcolepsy and OSA in phase 3 studies. This study evaluated the long-term safety and…
March 02, 2019
Introduction: Narcolepsy primarily begins in childhood/adolescence. Sodium oxybate (SXB) was evaluated as a treatment for narcolepsy in children/adolescents in a placebo-controlled, randomized-withdrawal study with open-label extension (OLE). The long-term evaluation of depression, anxiety, and…
March 02, 2019
Objective: To evaluate the long-term efficacy and safety of sodium oxybate (SXB) treatment for narcolepsy in pediatric patients in a placebo-controlled, randomized-withdrawal study with an open-label evaluation.
March 02, 2019
Objective: To evaluate the long-term efficacy and safety of sodium oxybate (SXB) treatment for narcolepsy in pediatric patients in a placebo-controlled, randomized-withdrawal study with an open-label evaluation.
March 02, 2019
OBJECTIVE: To assess the use of antidepressants, stimulants (amphetamine/methylphenidate), wake promoting agents (WPAs; modafinil/armodafinil), and sedative/hypnotics in patients with obstructive sleep apnea (OSA). METHODS: A retrospective analysis of US healthcare claims (Symphony Healthcare…
December 15, 2017
We evaluated the effects of adjunctive brexpiprazole on chronobiologic parameters of sleep in patients with MDD and inadequate response to antidepressant therapy.
November 29, 2017
A case report of a patient with refractory narcolepsy complicated by treatment emergent psychiatric side effects.
Back to Top